Circulating Tumor Cell Copy-Number Heterogeneity in ALK-Rearranged Non-Small-Cell Lung Cancer Resistant to ALK Inhibitors

Researchers provided in-depth investigation of copy number alteration heterogeneity in phenotypically characterized circulating tumor cells at resistance to Anaplastic Lymphoma Kinase (ALK)-tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.